Blue Light Cystoscopy: Indications and Outcomes
Autor: | Kamal S. Pohar |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Light Urology 030232 urology & nephrology Disease Cancer recurrence law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law medicine Humans In patient Neoplasm Staging Randomized Controlled Trials as Topic Photosensitizing Agents Bladder cancer medicine.diagnostic_test business.industry Disease progression Aminolevulinic Acid Cystoscopy General Medicine medicine.disease Administration Intravesical Blue light cystoscopy Urinary Bladder Neoplasms 030220 oncology & carcinogenesis Disease Progression Radiology Neoplasm Recurrence Local business |
Zdroj: | Current Urology Reports. 21 |
ISSN: | 1534-6285 1527-2737 |
DOI: | 10.1007/s11934-020-0966-5 |
Popis: | It has been firmly established that hexaminolevulinate-assisted blue light cystoscopy (HAL-BLC) reduces cancer recurrence rates. This review explores the impact of HAL-BLC on other meaningful outcomes in patients with bladder cancer, including disease progression, and earlier detection of disease at the time of surveillance cystoscopy. A randomized clinical trial confirmed earlier implementation of HAL-BLC at the time of surveillance cystoscopy increased identification of cancerous lesions, including those of high grade, when compared with white light cystoscopy. In addition, the evidence is evolving that the use of HAL-BLC at the time of endoscopic treatment of high-risk tumors may lead to lower rates of progression to muscle invasion, and this in part may be due to better risk stratification leading to changes in treatment plan. The clinical contexts for the use of HAL-BLC are broader than prior knowledge. It is also becoming more clear that the positive impact of HAL-BLC is likely more than just reducing cancer recurrence rates, and patients would benefit from the technology at many time points in the management and follow-up of their disease. |
Databáze: | OpenAIRE |
Externí odkaz: |